Dhansa Labs bets ₹150 cr on green energy while its core margins compress
A ₹30 cr atrazine capex and ₹120 cr CBG project anchor a 20% FY27 growth guide, but working capital and margin pressure are the immediate headwinds.
What's new
- Atrazine expansion capex of ₹30 crore starts August FY27; stabilised by year-end, contributing ₹40 crore to FY27 revenue.
- CBG project capex ₹120 crore; financial closure achieved with ₹85 crore debt and ₹36 crore warrant equity.
- FY26 revenue rose 10.8% to ₹14,154 lakh, but EBITDA margin compressed to 8.6% on chemical price deflation.
- Trade receivables jumped ₹15 crore in FY26 due to export logistics delays, now expected to normalise in H1 FY27.
Themes from the call
Demand
Export recovery is underway as geopolitical logistics delays normalise, but domestic agrochemical pricing remains deflated through FY26.
Margins
EBITDA margin fell to 8.6% on chemical price deflation; PAT margin was 3.9%, hit further by a one-off deferred tax gain in the prior year.
Capital allocation
Three-project capex totalling ₹290 crore (₹30 cr atrazine, ₹120 cr CBG, ₹140 cr bio-pellets) is funded by debt, warrant equity, and accruals over a 1-1.5 year cycle.
Guidance watch
- FY27 consolidated revenue growth guided at 20%, with no segment breakdown.
- Atrazine to deliver ₹120-140 crore annual revenue upon full stabilisation, with ₹40 crore partial contribution in FY27.
- CBG commercial operations targeted for July 2027 with an 8-10 year offtake contract signed.
- Bio-pellets capex of ₹140 crore is sequenced after CBG financial closure.
Risk flags
- Working capital pressure: trade receivables up ₹15 crore in FY26, with management defending the timing of capex against an operating cash flow decline.
- Pat margin at 3.9% is depressed by prior-year non-recurring deferred tax gain, making year-on-year margin comparison misleading.
- CBG and bio-pellet projects are in early stages; bio-pellets financial closure is pending and capex of ₹140 crore is not yet funded.
- The 20% FY27 growth guide was extracted under Q&A questioning and is described as directional with no segment breakdown.
Key quotes
-
"Upon stabilization, the project has the potential to contribute approximately 120-140 crore in additional annual revenue."
— Dhansa Labs management, prepared remarks on atrazine expansion -
"Working capital pressures (trade receivables up Rs 15 crore), operating cash flow decline, and PAT margin compression."
— Tijori analysis summary of Q&A
The brief
Dhansa Labs is pivoting toward green energy while its core agrochemical margins are under pressure. The ₹30 crore atrazine expansion is a manageable brownfield bet with clear ₹120-140 crore revenue potential, but the ₹120 crore CBG and ₹140 crore bio-pellet projects represent a far larger commitment to a sector where the company has no operating track record. The green energy pivot is the right long-term strategy, but the sequencing matters — the company is funding it with debt and warrant equity while its operating cash flow declined in FY26 and receivables ballooned. Management says the receivables will normalise in H1 FY27 as logistics stabilise. The 20% FY27 revenue growth guide is broad and was extracted under questioning, offering no visibility into which parts of the business will drive it. The atrazine capex offers the most near-term certainty. The CBG project's binding 8-10 year offtake is a positive, but the bio-pellets project is early-stage and its ₹140 crore capex is not yet funded. The margin compression is real: EBITDA margin at 8.6% reflects genuine pricing pressure, not just one-off items. The question for investors is whether the green energy bet will be funded by a recovering core business or by balance sheet debt. The answer will depend on how quickly export logistics normalise and how well the CBG project executes through its ramp phase.
Dhansa's agrochemical core needs to generate the cash flow before the green energy bets can pay off.